ALVR Logo

AlloVir, Inc. (ALVR) 

NASDAQ
Market Cap
$87.32M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
44 of 809
Rank in Industry
36 of 445

Largest Insider Buys in Sector

ALVR Stock Price History Chart

ALVR Stock Performance

About AlloVir, Inc.

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Insider Activity of AlloVir, Inc.

Over the last 12 months, insiders at AlloVir, Inc. have bought $10.99M and sold $313,568 worth of AlloVir, Inc. stock.

On average, over the past 5 years, insiders at AlloVir, Inc. have bought $36.7M and sold $13.12M worth of stock each year.

Highest buying activity among insiders over the last 12 months: GILEAD SCIENCES, INC. (10 percent owner) — $43.96M.

The last purchase of 2,930,870 shares for transaction amount of $10.99M was made by GILEAD SCIENCES, INC. (10 percent owner) on 2023‑06‑27.

List of Insider Buy and Sell Transactions, AlloVir, Inc.

2024-05-21SaleBrainard DianaChief Executive Officer
5,149
0.0045%
$0.79$4,080-5.13%
2024-05-17SaleSinha VikasSee Remarks
3,143
0.0027%
$0.75$2,355-2.37%
2024-05-17SaleBrainard DianaChief Executive Officer
3,075
0.0026%
$0.75$2,304-2.37%
2024-05-17SaleMiller EdwardGeneral Counsel
420
0.0004%
$0.75$315-2.37%
2024-05-17SaleHagen Brett RChief Accounting Officer
541
0.0005%
$0.75$405-2.37%
2024-05-03SaleSinha VikasSee Remarks
4,957
0.0043%
$0.80$3,946-4.61%
2024-05-03SaleBrainard DianaChief Executive Officer
10,240
0.0089%
$0.80$8,151-4.61%
2024-05-03SaleMiller EdwardGeneral Counsel
2,311
0.002%
$0.80$1,840-4.61%
2024-05-03SaleHagen Brett RChief Accounting Officer
1,597
0.0014%
$0.80$1,271-4.61%
2024-04-22SaleSinha VikasSee Remarks
1,857
0.0016%
$0.75$1,393+1.42%
2024-04-22SaleMiller EdwardGeneral Counsel
757
0.0007%
$0.75$568+1.42%
2024-04-22SaleHagen Brett RChief Accounting Officer
480
0.0004%
$0.75$360+1.42%
2024-04-19SaleSinha VikasSee Remarks
1,521
0.0013%
$0.75$1,142+2.93%
2024-04-19SaleBrainard DianaChief Executive Officer
9,601
0.0084%
$0.75$7,207+2.93%
2024-04-19SaleMiller EdwardGeneral Counsel
626
0.0005%
$0.75$470+2.93%
2024-04-19SaleHagen Brett RChief Accounting Officer
473
0.0004%
$0.75$355+2.93%
2024-04-02SaleSinha VikasSee Remarks
885
0.0008%
$0.77$683-1.29%
2024-04-02SaleBrainard DianaChief Executive Officer
1,533
0.0014%
$0.77$1,183-1.29%
2024-04-02SaleMiller EdwardGeneral Counsel
368
0.0003%
$0.77$284-1.29%
2024-04-02SaleHagen Brett RChief Accounting Officer
281
0.0002%
$0.77$217-1.29%

Insider Historical Profitability

3.91%
GILEAD SCIENCES, INC.10 percent owner
16635286
14.5843%
$0.7610
Sinha VikasSee Remarks
1129996
1.0041%
$0.76026
Brainard DianaChief Executive Officer
784471
0.7209%
$0.76125+5.55%
Miller EdwardGeneral Counsel
220496
0.1976%
$0.76015
Hagen Brett RChief Accounting Officer
75481
0.0696%
$0.76035
Wilson John Robertdirector
3164954
2.7747%
$0.7603
Vera Juandirector
2339928
2.0514%
$0.7609
Leen Ann M.Chief Scientific Officer
2288154
2.006%
$0.76012
Brenner Malcolmdirector
818663
0.7177%
$0.76011
Melian AgustinChief Medical Officer
453529
0.3976%
$0.7608
Jovan-Embiricos Moranadirector
342693
0.3004%
$0.7617+5.55%
VAN BEEK JEROEN BChief Commercial Officer
333726
0.2926%
$0.76134+5.55%
Hallal Daviddirector
138153
0.1211%
$0.7607
Atillasoy ErcemSee Remarks
131372
0.1152%
$0.7618+5.55%
Bornstein Jeffrey S
40197
0.0352%
$0.7621+0.64%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Ecor1 Capital Llc$8.53M9.8211.29MNew+$8.53M0.22
Artal Group S A$4.98M5.746.6M0%+$00.03
Octagon Capital Advisors LP$3.17M3.654.2MNew+$3.17M0.42
BlackRock$2.56M2.943.39M-3.98%-$105,898.13<0.0001
Millennium Management LLC$2.22M2.562.94M-24.63%-$725,761.69<0.01
The Vanguard Group$2.21M2.542.92M-0.55%-$12,192.39<0.0001
Irenic Capital Management Lp$1.95M2.242.58MNew+$1.95M0.54
Redmile Group$1.44M1.661.91M0%+$00.05
Acadian Asset Management$1.2M1.381.59M+694.58%+$1.05M<0.01
Geode Capital Management$961,803.001.111.27M+1.65%+$15,616.29<0.0001
State Street$889,465.001.031.18M+8.99%+$73,340.01<0.0001
American International Group$19.79M11.15M-0.02%-$3,721.610.07
Acuitas Investments, LLC$739,500.000.85979,600New+$739,500.000.39
D. E. Shaw & Co.$656,659.000.76869,862+244.31%+$465,941.77<0.01
Renaissance Technologies$650,000.000.75861,494+13.06%+$75,094.95<0.01
Charles Schwab$347,878.000.4460,826-3.15%-$11,328.04<0.0001
Northern Trust$339,309.000.39449,475+4.73%+$15,322.22<0.0001
Marshall Wace$273,853.000.32365,136+12.47%+$30,358.61<0.0001
Morgan Stanley$267,029.000.31353,727-30.98%-$119,870.79<0.0001
Two Sigma$239,942.000.28317,846+20.14%+$40,229.39<0.0001
Two Sigma Advisers LP$225,262.000.26298,400+202.02%+$150,677.93<0.0001
Fidelity Investments$205,210.000.24271,837-95.22%-$4.09M<0.0001
Gsa Capital Partners Llp$171,000.000.2226,627+8.55%+$13,465.590.01
Pennant Capital Management Llc$162,832.000.19215,7000%+$00.03
Bml Capital Management Llc$151,330.000.17200,464New+$151,330.000.12
Tealwood Asset Management$135,039.000.16178,883New+$135,039.000.03
Goldman Sachs$121,156.000.14160,493-65.56%-$230,680.52<0.0001
BNY Mellon$120,348.000.14159,423-22.22%-$34,386.33<0.0001
Citadel Advisors LLC$110,366.000.13146,200-39.05%-$70,710.49<0.0001
Qube Research & Technologies$81,271.000.09107,658-45.36%-$67,457.84<0.0001
T. Rowe Price$74,000.000.0997,986+127.42%+$41,461.03<0.0001
AQR Capital$70,779.000.0893,759-24.63%-$23,131.00<0.0001
Susquehanna International Group$69,221.000.0891,695+155.43%+$42,120.67<0.0001
Samsara Biocapital Llc$62,155.000.0782,3360%+$00.01
Lido Advisors, LLC$59,951.000.0779,4160%+$0<0.0001
Deutsche Bank$53,771.000.0670,751+227.64%+$37,359.49<0.0001
Dimensional Fund Advisors$52,668.000.0669,769-1.97%-$1,056.85<0.0001
RhumbLine Advisers$52,083.000.0668,999+8.46%+$4,061.78<0.0001
AllianceBernstein$48,638.000.0664,4300%+$0<0.0001
Verition Fund Management Llc$48,174.000.0663,815New+$48,174.00<0.01
Raymond James Financial Services Advisors Inc$45,671.000.0560,500+80.92%+$20,427.39<0.0001
UBS$41,900.000.0555,496-8.46%-$3,874.71<0.0001
Tudor Investment Corp Et Al$37,458.000.0449,6200%+$0<0.0001
Amundi$33,727.000.0445,4480%+$0<0.0001
Xtx Topco Ltd$35,073.000.0446,460-15.24%-$6,307.25<0.01
Bank of America$34,217.000.0445,381-35.32%-$18,684.72<0.0001
Barclays$27,000.000.0335,247-49.39%-$26,351.94<0.0001
JPMorgan Chase$22,786.000.0330,184-91.73%-$252,691.03<0.0001
Just Invest, LLC$21,468.000.0328,438+146.15%+$12,746.58<0.0001
Capstone Investment Advisors$20,571.000.0227,250+9%+$1,698.52<0.01